Clinical trials: Complex Regional Pain Syndrome Type I
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.
- Trial name
- CREATE-1 (NCT02504008)
- Testing
- AXS-02 (oral zoledronate)
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 190 people
- Sponsor
- Axsome Therapeutics, Inc.
Complex Regional Pain Syndrome I (CRPS I)
CRPS-RISE Outcomes Registry
The goal of this observational study is to learn about how well neridronate keeps working in the months after treatment. For 12 or up to 24 months while the registry is open participants will answer online survey questions about…
- Trial name
- NCT07811362
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Ambros Therapeutics, Inc.
RSD (Reflex Sympathetic Dystrophy), CRPS - Complex Regional Pain Syndrome Type I
Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia
Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and Fibromyalgia represent progressive systemic pain conditions which often worsen over time.
- Conditions
- RSD (Reflex Sympathetic Dystrophy), CRPS - Complex Regional Pain Syndrome Type I, Fibromyalgia
- Trial name
- ADcSVF-CRPS (NCT02987855)
- Testing
- Lipoaspiration, ADcSVF isolation, Normal Saline IV
- Where
- 2 sites in United States, Honduras
- Sponsor
- Healeon Medical Inc
Complex Regional Pain Syndrome Type I
Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1
A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
- Trial name
- NCT07857733
- Testing
- Neridronate
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Ambros Therapeutics, Inc.
Complex Regional Pain Syndrome, Type I
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
- Trial name
- CRPS-002 (NCT00109772)
- Testing
- lenalidomide
- Where
- 27 sites in United States
- Volunteers
- 184 people
- Sponsor
- Celgene Corporation
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Complex Regional Pain Syndrome, Type I
Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I
This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I).
- Trial name
- NCT02402530
- Testing
- Neridronic acid 62.5 mg
- Where
- 59 sites in United States, Germany and 1 more
- Volunteers
- 459 people
- Sponsor
- Grünenthal GmbH
Complex Regional Pain Syndrome (CRPS)
TARGET Post-Approval Study
The purpose of this prospective, multicenter, single arm post-approval study is to demonstrate continued safety of the Axium and Proclaim Neurostimulator System for dorsal root ganglion (DRG) stimulation.
- Trial name
- TARGET PAS (NCT02800863)
- Testing
- Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System), Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
- Where
- 44 sites in United States
- Volunteers
- 426 people
- Sponsor
- Abbott Medical Devices
Complex Regional Pain Syndrome Type I
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
- Trial name
- CRPS-RISE (NCT07210515)
- Testing
- Neridronate
- Where
- 31 sites in United States
- Volunteers
- 270 people
- Sponsor
- Ambros Therapeutics, Inc.